A cost-benefit analysis using a willingness-to-pay questionnaire of intranasal budesonide for seasonal allergic rhinitis

Annals of Allergy, Asthma and Immunology

Volumn 84, Issue 1, 2000, Pages 55-62

  Keith, Paul K ^a   Haddon, Jennifer ^b   Birch, Stephen ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b Astra Pharma Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE;

ADULT; ALLERGIC RHINITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST OF ILLNESS; DOUBLE BLIND PROCEDURE; FEMALE; HEALTH CARE COST; HUMAN; INHALER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033964932     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)62741-X     Document Type: Article

References (25)

1. Turkeltaub PC, Gergen PJ. Prevalence of upper and lower respiratory conditions in the US population by social and environmental factors: data from the second National Health and Nutrition Examination Survey, 1976 to 1980 (NHANES II). Ann Allergy 1991;67:147-154.
2. Newman LJ, Platts-Mills TA, Phillips CD, et al. Chronic sinusitis. Relationship of computed tomographic findings to allergy, asthma, and eosinophilia. JAMA 1994;271:363-367.
3. Hurst DS. Association of otitis media with effusion and allergy as demonstrated by intradermal skin testing and eosinophil cationic protein levels in both middle ear effusions and mucosal biopsies. Laryngoscope 1996;106: 1128-1137.
4. Foresi A, Pelucchi A, Gherson G, et al. Once daily intranasal fluticasone propionate (200 micrograms) reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis. J Allergy Clin Immunol 1996;98:274-282.
5. Fireman P. Treatment of allergic rhinitis: effect on occupation productivity and work force costs. Allergy Asthma Proc 1997;18:63-67.
6. McMenamin P. Costs of hay fever in the United States in 1990. Ann Allergy 1994;73:35-39.
7. Malone DC, Lawson KA, Smith DH, et al. A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol 1997;99:22-27.
8. Yang WH, Dolovich J, Drouin MA, et al. Comparison of budesonide turbuhaler with budesonide aqua in the treatment of seasonal allergic rhinitis. Can Respir J 1998;5:455-460.
9. Drug Benefit Formulary/Comparative Drug Index, No. 33, 1993.
10. Chedoke-McMaster Corporate hospital Cost Data Base, Centre for Health Economics and Policy Analysis, McMaster University, Hamilton, Ontario. 1993.
11. Schedule of Benefits Physician Services under the Health Insurance Act, October 1, 1992, Ontario Ministry of Health, Toronto. 1992.
12. Employment, earning and hours, September 1993. Statistics Canada - Cat. No. 72-002. 1993.
13. Thompson MS, Read JL, Liang M. Feasibility of willingness-to-pay measurement in chronic arthritis. Med Decis Making 1984;4:195-215.
14. 2B Profile: Urban Forward Sortation Areas (FSAs): Statistics Canada 1991 Census Electronic Dictionary. 1991 Census of Canada. Catalogue No. 92-301D E. 1992.
15. 2B Profile: Urban Forward Sortation Areas (FSAs): Statistics Canada 1991 Census Electronic Dictionary. 1991 Census of Canada. Catalogue No. 92-301D E. 1992.
16. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991;21: 77-83.
17. Pauker SG, Kassirer JP. Decision analysis. N Engl J Med 1987;316: 250-258.
18. Dupont WD, Plummer WDJ. Power and sample size calculations. A review and computer program. Control Clin Trials 1990;11:116-128.
19. Juniper EF, Willras DG, Guyatt GH, Ferrie PJ. Aqueous beclomethasone dipropionate nasal spray in the treatment of seasonal (ragweed) rhinitis. Can Med Assoc J 1992;147:887-892.
20. Juniper EF, Guyatt GH, O'Byrne PM, Viveiros M. Aqueous beclomethasone diproprionate nasal spray: regular versus "as required" use in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 1990;86:380-386.
21. O'Byrne P, Cuddy L, Taylor DW, et al. Efficacy and cost benefit of inhaled corticosteroids in patients considered to have mild asthma in primary care practice. Can Respir J 1996;3: 169-175.
22. Ross CK, Steward CA, Sinacore JM. A comparative study of seven measures of patient satisfaction. Med Care 1995; 33:392-406.
23. Luce BR, Elixhauser A. Estimating costs in the economic evaluation of medical technologies. Int J Technol Assess Health Care 1990;6:57-75.
24. Appel LJ, Steinberg EP, Powe NR, et al. Risk reduction from low osmolality contrast media. What do patients think it is worth? Med Care 1990;28: 324-337.
25. Thompson MS. Willingness to pay and accept risks to cure chronic disease. Am J Public Health 1986;76:392-396.